The Pharmaceutical Journal
Vol 269 No 7225 p733
23 November 2002

This article
Reprint
Photocopy

News summary

Two winners for Prix Galien award 2002

Herceptin (trastuzumab) and Glivec (imatinib) share this year's United Kingdom Prix Galien award for innovative pharmaceutical products, it was announced last week.

Trastuzumab, manufactured by Roche, is licensed for the treatment of metastatic breast cancer where tumours overexpress human epidermal growth factor receptor 2 (HER2). Imatinib, manufactured by Novartis Oncology, is licensed for the treatment of chronic myeloid leukaemia and malignant gastrointestinal stromal tumours.

Other finalists for the award included Avandia (rosiglitazone), Dovobet (calcipotriol and betamethasone), Enbrel (etanercept), Keppra (levetiracetam), Malarone (atovaquone and proguanil) and ViraferonPeg (peginterferon alpha-2b).